Four Federal Efforts to Monitor, Including RESULTS Act Progress
Other proposals aim to increase fraud enforcement, temper prior authorization, and modernize CLIA
Other proposals aim to increase fraud enforcement, temper prior authorization, and modernize CLIA
The $14.6 billion bust by federal prosecutors shows gaps that every laboratory should monitor
Read this overview of legislation and regulations governing laboratory marketing practices and learn tips to ensure these activities remain compliant
However, a new memo instructs federal prosecutors to ‘avoid overreach’ when parties cooperate with authorities
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing
Experts explain what the phase-in process will look like—and how labs can get ahead of the game.
Curious about how laboratory-developed tests are regulated in other countries? We compare in-house test guidance across six regions
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
Know where labs may fall foul of compliance requirements—and discover the actions your lab can take to mitigate the risk of noncompliance
Recent enforcement actions show that clinical laboratories must remain vigilant about compliance relating to these areas